Revenue Update on Trinity Biotech plc (ADR)(NASDAQ:TRIB)

Trinity Biotech plc (ADR)(NASDAQ:TRIB) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 21, 2016. Company reported revenue of $26.29M. Analysts estimated a revenue of $24.80M. Earnings per share were $0.09. Analysts had estimated an EPS of $0.06.

Trinity Biotech plc (ADR) (TRIB) made into the market gainers list on Wednesdays trading session with the shares advancing 2.33% or 0.25 points. Due to strong positive momentum, the stock ended at $10.99, which is also near the day’s high of $11.08. The stock began the session at $10.8 and the volume stood at 80,224 shares. The 52-week high of the shares is $18.82 and the 52 week low is $9.2. The company has a current market capitalization of $263 M and it has 2,39,60,034 shares in outstanding.

Trinity Biotech plc (Trinity Biotech) develops acquires manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune infectious and sexually transmitted diseases diabetes and disorders of the liver and intestine. Trinity Biotech also is a provider of raw materials to the life sciences and research industries globally. Trinity Biotech markets its portfolio of almost 850 products to customers in approximately 100 countries around the world. The primary market for Trinity Biotech’s diagnostic products is the Americas (which consists principally of North America and South America). Its products are classified as point-of-care emergency medicine clinical laboratory and blood bank screening. The Company markets products under Uni-Gold Recombigen Meritas Captia MicroTrak Bartels MarDx MarBlot Premier Ultra2 ImmuBlot ImmuGlo ImmuLisa OTOblot and EZ.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *